Abstract: Disclosed is a method for preparing a stabilized enzyme dispersion wherein the dispersion is prepared by precipitating a water-soluble polymer from a single phase, aqueous solution to form an aqueous dispersion, and before, simultaneously with or after precipitating the polymer, contacting the dissolved or dispersed polymer with an aqueous solution or fine aqueous dispersion of an enzyme without any covalent bonding between the polymer and the enzyme. Also disclosed is a clear solution for use in the method.

Abstract: Novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which a substituted alkyl chain forms part of the N-substituent, the compounds thus having the general formula I ##STR1## wherein Y is ##STR2## wherein R.sup.1 and R.sup.2 independently are C.sub.3-8 cycloalkyl phenyl or thienyl all of which may be optionally substituted with halogen, trifluoromethyl, C.sub.1-16 alkyl or C.sub.1-6 alkoxy;s is 1, 2 or 3;x is --CH.sub.2 --, --O-- or ##STR3## -wherein R.sup.3 is hydrogen or C.sub.1-6 -alkyl; r is 2, 3 or 4; R.sup.4 and R.sup.5 each represents hydrogen or may together represent a bond and R.sup.6 is OH or C.sub.1-8 -alkoxy; and pharmaceutically acceptable acid addition salts are potent inhibitors of GABA uptake from the synaptic cleft.

Abstract: A device for monitoring a delivery system comprising a volumetric micropump, a measuring element or sensor located in the infusion line, a matching system and an analyzing system. The devices are preferably for use in insulin administration when treating type-I diabetes and in analytical laboratories, the chemical and pharmaceutical industries and other technologies.

Abstract: New substituted urea compounds of formula I, or a pharmaceutically acceptable salt thereof: ##STR1## whereinA is ##STR2## wherein R.sup.3 is an oxadiazol, substituted with C.sub.1-8 -alkyl, C.sub.2-8 -alkenyl, C.sub.2-8 alkynyl, C.sub.3-7 cycloalkyl, benzyl, phenyl, C.sub.1-6 -alkoxy, C.sub.1-6 -alkylthio, amino or alkylamino;R.sup.2 is --H or lower alkyl;X is O or S; andR.sup.1 is a group of formula II, III, IV or V ##STR3## where n is 2 or 3, p is 1 or 2, q is 1 to 3, r is 1-3 and R.sup.4 and R.sup.5 are H, C.sub.1-7 alkyl or C.sub.3-6 cycloalkyl; and N-oxides thereof.The compounds are useful in pharmaceutical preparations for treating psychotic disorders, nausea and vomiting.

Abstract: The present invention relates to therapeutically active azacyclic or azabicyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful as stimulants of the cognitive function of the forebrain and hippocampus of mammals and especially in the treatment of Alzheimer's disease.

Abstract: Novel [1]benzothieno[2,3-b]pyrazine-2,3(1H,4H)-diones or tautomeric forms thereof of the general formula (I) ##STR1## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 independently represent hydrogen, halogen, alkyl, alkoxy or trifluoromethyl.The compounds are useful for treating a central nervous system ailment associated with the NMDA receptor-associated glycine site.

Abstract: A method for treating patients suffering from bleeding disorders not caused by clotting factor defects or clotting factor inhibitors, as well as a novel composition for use in treating bleeding disorders as disclosed. The method includes administering to a patient a composition comprising an effective haemostatic amount of factor VIIa, and is particularly effective in treating patients suffering from thrombocytopenia and von Willebrand's disease, as well as other platelet disorders. A composition suitable for use in treating such bleeding disorders comprises purified factor VIIa in a concentration of at least 25 .mu.g/ ml.

Abstract: A disubstituted piperazine compound having the formula I ##STR1## wherein R.sup.1 is thienyl or phenyl, which may be substituted with C.sub.1-6 -alkyl or halogen, and R.sup.2 is thienyl, which may be substituted with C.sub.1-6 -alkyl or halogen, and R.sup.3 is C.sub.1-8 -alkyl, C.sub.3-8 -alkenyl or C.sub.3-8 -cycloalkyl which all may be substituted with hydroxy, oximino or keto in any position giving a stable tertiary amine or R.sup.3 is C.sub.1-8 -alkyl or C.sub.3-8 -alkenyl which in any position may be substituted as above, but is terminally substituted with phenoxy, phenyl, thienyl, furyl, methoxy or --CN and pharmaceutically acceptable acid addition salts thereof.The compounds are useful in the treatment of mental disorders in which a dopaminergic deficit is implicated.

Abstract: 1-carboxyalkylquinoxaline-2,3(1H,4H)-dione compounds or tautomeric forms thereof of the formula ##STR1## wherein R represents hydrogen, C.sub.1-6 -alkyl, including branched chains, or aralkyl and n represents the number from 0 to 5;R.sup.4 represents hydrogen or hydroxy;R.sup.5, R.sup.6, R.sup.7 and R.sup.8 independently represent hydrogen, nitro, halogen, alkoxy, aryloxy, aralkoxy, C.sub.1-6 -alkyl including branched chains, or aryl;R.sup.9 represents hydrogen, lower alkyl, or aryl;R.sup.10 represents hydrogen, or alkyl.The compounds are useful in the treatment of neurological and psychiatric diseases.

Abstract: The present invention relates to novel human insulin analogues exhibiting a low ability to associate in solution, a method for the preparation of such insulin analogues, insulin preparations containing the human insulin analogues of the invention and a method of treating Diabetes Mellitus using these human insulin analogues.

Abstract: Synthetic yeast leader peptides are disclosed which aid in extracellular secretion of heterologous proteins made recombinantly in yeast.

Abstract: Lipase is immobilized by adsorption on a polymethacrylic acid ester resin such as polymethylmethacrylate cross-linked with divinyl benzene. The resin is preferably a particulate, macroporous resin having an average pore radius of 100-200 .ANG., a total surface area of 25-150 m.sup.2 /g and a particle size of 100-1,000 .mu.m. The lipase may be obtained from Mucor miehei, Candida antarctica, Pseudomonas cepacia or Humicola lanuginosa. The immobilized lipase may be dried and is used for interesterifying an ester, hydrolyzing an ester or synthesizing an ester. Interesterification can be carried out continuously in a fixed-bed column.

Abstract: This invention relates to stabilized enzymatic liquid detergent compositions useful in cleaning a wide range of items including hard surfaces and soft goods such as textiles both for commercial and home use. The stabilization of the enzyme is obtained via the addition of a surfactant composition.

Abstract: Heterocyclic dihydroxyquinoxaline compounds having the formula ##STR1## wherein R.sup.1 is hydroxy; andR.sup.5 and R.sup.6 together form a fused phenyl, cyclohexyl or pyridyl ring, which is optionally substituted with halogen or CN; and R.sup.7 and R.sup.8 independently are hydrogen, hydroxy, NO.sub.2, halogen, CN, CF.sub.3, C.sub.1-4 -alkoxy, acetyl, SO.sub.2 NHCOCO.sub.2 Et, SO.sub.2 NR'R' or SO.sub.2 R', wherein R' is hydrogen or C.sub.1-4 -alkyl; orR.sup.5 and R.sup.6 independently are hydroxy, hydrogen, NO.sub.2, halogen, CN, CF.sub.3, C.sub.1-4 -alkoxy, acetyl, SO.sub.2 NHCOCO.sub.2 Et, SO.sub.2 NR'R' or SO.sub.2 R', wherein R' is hydrogen or C.sub.1-4 -alkyl; and R.sup.7 and R.sup.8 together form a fused phenyl, cyclohexyl or pyridyl ring which is optionally substituted with halogen or CN.The invention also relates to a method of preparing the compounds, pharmaceutical compositions thereof, and their use.

Abstract: Novel aryloxyphenylpropylamines having the formula ##STR1## wherein X is H, cyano, halogen, halogenoalkyl, C.sub.1-6 -alkoxy, C.sub.1-6 -alkyl, C.sub.1-5 -alkanoyl, C.sub.3-5 -alkylene, aryloxy or aralkoxy, andR is 3,4-methylenedioxy, aryl or heteroaryl which are optionally substituted with one or more cyano, halogeno, C.sub.1-6 -alkyl, C.sub.1-6 -alkoxy, C.sub.1-6 -alkenyl, trifluoromethyl, C.sub.3-5 -alkylene, aryloxy or aralkoxy; andR.sup.1 and R.sup.2 independently is C.sub.1-10 -alkyl, C.sub.3-7 -cycloalkyl, C.sub.2-10 -alkenyl, C.sub.3-6 -cycloalkyl-C.sub.1-5 -alkyl, optionally substituted with C.sub.1-5 -alkoxy or cyano;R.sup.1 and R.sup.2 may together form a carbocyclic ring and a salt thereof with a pharmaceutically acceptable acid,provided however that R.sup.1 is not C.sub.3-7 -cycloalkyl, C.sub.1-10 -alkyl, or alkenyl which may be straight, branched or cyclic, unsubstituted or substituted with C.sub.1-4 -alkoxy, aryloxy or cycloalkyl or cycloalkylalkyl, when X is H and R.sup.2 is a methyl group.

Abstract: Contaminants containing non-polar neutral lipid are removed from a solvent that has been used for dry cleaning by placing used solvent in contact with a lipase, which is stable and exhibits an activity in the solvent, or with an immobilized product of said lipase, and with an adsorbent.

Abstract: Indole derivatives of formula (I) ##STR1## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 may be hydrogen or lower alkyl optionally substituted by halogen; A.sup.1 represents a straight or branched alkylene chain containing from 2 to 4 carbon atoms; R.sup.5 is hydrogen or a straight or branched alkyl group; A.sup.2 is a straight or branched, saturated or unsaturated hydrocarbon chain containing from 2 to 6 carbon atoms; and R.sup.6 is selected from a group consisting of various structures, have been found to exhibit central nervous system activities.

Abstract: New imidazoquinoxaline compounds having the general formula I ##STR1## wherein ##STR2## wherein R.sup.1 and R.sup.2 independently are hydrogen, straight or branched C.sub.1-6 -alkyl, or C.sub.3-7 -cycloalkyl; R.sup.3 is hydrogen, straight or branched C.sub.1-6 -alkyl, straight or branched C.sub.2-6 -alkenyl, or aralkyl or aroylalkyl which may optionally be substituted with halogen or C.sub.1-6 -alkoxy; R.sup.4 amd R.sup.5 independently are hydrogen, halogen, C.sub.1-6 -alkyl or trifluoromethyl.The compounds are useful in psychopharmaceutical preparations as anticonvulsants, anxiolytics, hypnotics and in improving the cognitive function of the brain of mammals.

Abstract: New imidazoquinoxaline compounds having the general formula I ##STR1## wherein R.sup.1 and R.sup.2 independently are hydrogen, straight or branched C.sub.1-6 -alkyl, or C.sub.3-7 -cycloalkyl; R.sup.3 is hydrogen, straight or branched C.sub.1-6 -alkyl, straight or branched C.sub.2-6 -alkenyl, or aralkyl or aroylalkyl which may optionally be substituted with halogen or C.sub.1-6 -alkoxy; R.sup.4 and R.sup.5 independently are hydrogen, halogen, C.sub.1-6 -alkyl or trifluoromethyl.The compounds are useful in psychopharmaceutical preparations as anticonvolusants, anxiolytics, hypnotics and in improving the cognitive function of the brain of mammals.

Abstract: Novel piperidine compounds having the formula I ##STR1## wherein R.sup.3 is 3,4-methylenedioxyphenyl, phenyl, naphthyl, which are optionally substituted with one or two halogen, amino, C.sub.1-6 -alkyl mono-or disubstituted amino group, C.sub.1-6 -alkoxy, cyano, mono-, di- or trihalogenated C.sub.1-6 -alkyl, C.sub.2-6 -alkenyl, C.sub.1-6 alkyl, C.sub.3-5 -alkylene, trifluoromethoxy, or trifluoromethyl groups,R.sup.1 is hydrogen, straight or branched C.sub.1-8 -alkyl, C.sub.1-8 -alkoxy-C.sub.1-8 -alkyl, C.sub.3-8 -cycloalkyl, C.sub.2-6 -alkenyl, C.sub.4-8 -cycloalkylalkyl, C.sub.2-6 -alkynylZ is hydrogen, straight or branched C.sub.1-8 -alkyl,Y is O or SX is O, S or NR, wherein R is hydrogen or C.sub.1-4 -alkylor a salt thereof with a pharmaceutically acceptable acid.The novel compounds are useful in the treatment of anoxia, traumatic injury, ischemia, migraine and epilepsy.